Tags

Type your tag names separated by a space and hit enter

iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
Ann Pharmacother. 2017 Nov; 51(11):990-999.AP

Abstract

OBJECTIVE

To review the safety and efficacy of iGlarLixi, a titratable fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide, a glucagon-like peptide-1 receptor agonist.

DATA SOURCES

A literature search of MEDLINE for all English-language primary articles through June 2016, using the terms LixiLan, iGlarLixi and insulin glargine and lixisenatide, and a search of abstracts presented at the 2016 Scientific Sessions of the American Diabetes Association were performed.

STUDY SELECTION AND DATA EXTRACTION

All studies assessing the efficacy and/or safety of iGlarLixi were evaluated.

DATA SYNTHESIS

iGlarLixi has been approved in the United States for glycemic control in people with type 2 diabetes (T2D) inadequately controlled with basal insulin (<60 U/d) or lixisenatide. In clinical trials, iGlarLixi was associated with significantly greater reductions from baseline in glycated hemoglobin A1C (A1C) than iGlar or lixisenatide alone. Reductions in postprandial glucose were also greater with iGlarLixi than with iGlar or lixisenatide. iGlarLixi was weight neutral compared with the weight gain with iGlar and loss with lixisenatide alone, and there was no increase in hypoglycemia with iGlarLixi compared with iGlar despite the greater A1C reduction. Gastrointestinal events, frequently associated with lixisenatide, were less common with iGlarLixi. Potential drawbacks of iGlarLixi include reduced flexibility in dosing and the absence of long-term efficacy and safety data.

CONCLUSIONS

iGlarLixi is a titratable fixed-ratio combination that shows improved efficacy and comparable or improved safety outcomes relative to its separate constituents, offering an alternative approach to intensification of therapy in T2D.

Authors+Show Affiliations

1 School of Pharmacy, MCPHS University, Boston, MA, USA.2 University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

28645216

Citation

Goldman, Jennifer, and Jennifer M. Trujillo. "IGlarLixi: a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes." The Annals of Pharmacotherapy, vol. 51, no. 11, 2017, pp. 990-999.
Goldman J, Trujillo JM. IGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. Ann Pharmacother. 2017;51(11):990-999.
Goldman, J., & Trujillo, J. M. (2017). IGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. The Annals of Pharmacotherapy, 51(11), 990-999. https://doi.org/10.1177/1060028017717281
Goldman J, Trujillo JM. IGlarLixi: a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. Ann Pharmacother. 2017;51(11):990-999. PubMed PMID: 28645216.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes. AU - Goldman,Jennifer, AU - Trujillo,Jennifer M, Y1 - 2017/06/23/ PY - 2017/6/25/pubmed PY - 2018/2/7/medline PY - 2017/6/25/entrez KW - GLP-1 receptor agonist KW - fixed-ratio combination KW - insulin glargine KW - lixisenatide KW - type 2 diabetes SP - 990 EP - 999 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 51 IS - 11 N2 - OBJECTIVE: To review the safety and efficacy of iGlarLixi, a titratable fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide, a glucagon-like peptide-1 receptor agonist. DATA SOURCES: A literature search of MEDLINE for all English-language primary articles through June 2016, using the terms LixiLan, iGlarLixi and insulin glargine and lixisenatide, and a search of abstracts presented at the 2016 Scientific Sessions of the American Diabetes Association were performed. STUDY SELECTION AND DATA EXTRACTION: All studies assessing the efficacy and/or safety of iGlarLixi were evaluated. DATA SYNTHESIS: iGlarLixi has been approved in the United States for glycemic control in people with type 2 diabetes (T2D) inadequately controlled with basal insulin (<60 U/d) or lixisenatide. In clinical trials, iGlarLixi was associated with significantly greater reductions from baseline in glycated hemoglobin A1C (A1C) than iGlar or lixisenatide alone. Reductions in postprandial glucose were also greater with iGlarLixi than with iGlar or lixisenatide. iGlarLixi was weight neutral compared with the weight gain with iGlar and loss with lixisenatide alone, and there was no increase in hypoglycemia with iGlarLixi compared with iGlar despite the greater A1C reduction. Gastrointestinal events, frequently associated with lixisenatide, were less common with iGlarLixi. Potential drawbacks of iGlarLixi include reduced flexibility in dosing and the absence of long-term efficacy and safety data. CONCLUSIONS: iGlarLixi is a titratable fixed-ratio combination that shows improved efficacy and comparable or improved safety outcomes relative to its separate constituents, offering an alternative approach to intensification of therapy in T2D. SN - 1542-6270 UR - https://www.unboundmedicine.com/medline/citation/28645216/iGlarLixi:_A_Fixed_Ratio_Combination_of_Insulin_Glargine_100_U/mL_and_Lixisenatide_for_the_Treatment_of_Type_2_Diabetes_ L2 - http://journals.sagepub.com/doi/full/10.1177/1060028017717281?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -